AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 530578: 2,6-Difluorobenzoic acid, tetradecyl ester

Chemical compound data from PubChem database. IUPAC Name: tetradecyl 2,6-difluorobenzoate. Molecular Formula: C21H32F2O2. Molecular Weight: 354.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Deconstructing patient centred communication and uncovering shared decision making: an observational study

Background
          Patient centred communication (PCC) has been described as a method for doctor-patient communication. The principles of shared decision making (SDM) have been proposed more recently.
        
        
          Aims
          This study aimed to examine PCC and SDM empirically with respect to their mutual association, the variation in practitioners' working styles, and the associations with patient characteristics.
        
        
          Methods
          Sixty general practitioners recruited 596 adult patients who gave written consent to have their consultations videotaped. The tapes were assessed by two researchers, using a standardised instrument for global communication. For the purpose of this exploratory study, scales for PCC and SDM were based on subsamples of items in the MAAS.
        
        
          Results
          The scales for PCC and SDM were weakly associated (Pearson correlation: 0.25). Physicians varied more on SDM than on PCC. The intracluster correlation of the PCC and SDM scales were, respectively, 0.34 and 0.19. However, hypotheses regarding associations with patient characteristics were not confirmed. Neither PCC nor SDM scores were related to patient gender, education, age, functional health status or existence of chronic conditions.
        
        
          Conclusion
          The study provides evidence that PCC and SDM can be differentiated and comprise approaches to communication between clinicians and patients which may be more clearly distinguished by further focused research and training developments.
Managed Care Individual Provider Network Data: December 31, 2017

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of health plans in New York State. Beginning in 2017, the PNDS includes Medicaid Managed Care (MMC), HIV Special Need Plans (SNP), Health and Recovery Plans (HARP), Child Health Plus (CHP), Programs of All-Inclusive Care for the Elderly (PACE), Non-PACE Managed Long-Term Care (MLTC) plans, Qualified Health Plans (QHP), Essential Plans (EP), and commercial plans (commercial plan reporting will be incomplete until Q2 2017). This dataset reflects individual provider data. Provider Network Data System information is self-reported by health plans. The PNDS data dictionary can be found at http://www.health.ny.gov/health_care/managed_care/docs/dictionary.pdf . To use the NYS Provider & Health Plan Look-Up Tool, click on the following link, https://pndslookup.health.ny.gov/ .
Compound 530138: Arg, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 5-[bis(trimethylsilylamino)methylideneamino]-2-(trimethylsilylamino)pentanoate. Molecular Formula: C18H46N4O2Si4. Molecular Weight: 462.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525505: 6-Methyl-4-thiaundecane

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-1-propylsulfanylheptane. Molecular Formula: C11H24S. Molecular Weight: 188.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529024: 2-Ethyl-4-methyl-1-propylbenzene

Chemical compound data from PubChem database. IUPAC Name: 2-ethyl-4-methyl-1-propylbenzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
AFCARS Report #27

This report provides preliminary estimates of Adoption and Foster Care Analysis and Reporting System (AFCARS) data for FY 2019. As states are permitted to resubmit AFCARS data, the estimates may change over time. This report reflects all AFCARS data received as of June 23, 2020 related to AFCARS reporting periods through September 30, 2019.

Metadata-only record linking to the original dataset. Open original dataset below.
Annual Report to Congress on State Child Welfare Expenditures reported on the CFS-101 (2020)

This report to Congress provides national totals of planned spending by service category for the Stephanie Tubbs Jones Child Welfare Services program and planned and actual spending by service category for the Promoting Safe and Stable Families program.

For questions on or to obtain Attachment B, please contact Linda Viales for assistance.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399694-T1: [Translated] SHOPPING VENTURE

A shopping trolley ( 10 ) has a basket ( 11 ), handle ( 12 ) and front and rear wheels ( 13, 14 ). The basket ( 11 ), tapered in plan view, has side walls ( 15, 16 ) interconnected by a front wall ( 17 ). The rear wall ( 19 ) is hingedly connected to the side walls ( 15, 16 ) and engages the rearward end of the floor ( 22 ), which is hingedly connected to the side walls ( 15, 16 ) or front wall ( 17 ). The floor ( 22 ) is downwardly inclined from the rearward end to the forward end. When the trolley ( 10 ) is nested with a similar trolley, the rear wall ( 19 ) is swung inwardly and upwardly, causing the floor ( 22 ) to be swung upwardly to be behind the front wall ( 17 ). Alternative the floor ( 22 ) may be folded e.g. in a concertina-like fashion, to be behind the front wall ( 17 ).
Business Rules PUF - PY2017

The Business Rules PUF (BR-PUF) is one of the files that make up the Marketplace PUF. The BR-PUF contains plan-level data on the application of rates, such as allowed relationships (e.g., spouse, dependents) and tobacco use. These data either originate from the Business Rules template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Publications Using SAMHSA DataBehavioral Health Barometer: North Carolina, 2014

This is a behavioral health report for the state of North Carolina. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
Endovascular treatment of huge saccular abdominal aortic aneurysm in a young Behcet patient: mid-term result

Background
          Abdominal aortic aneurysm formation is among the arterial complications of Behcet's disease. Weakness and fragility of aortic walls leads to the development of arterial complications like pseudoaneurysms.
        
        
          Case Presentation
          A case of huge saccular abdominal aortic aneurysm in a young Behcet patient who was successfully treated with endovascular stent graft placement is reported, diagnostic and interventional procedures are discussed, and mid-term follow-up results are presented.
        
        
          Conclusions
          Endovascular treatment of abdominal aortic aneurysm complications of young Behcet patients who are not suitable for open surgery and need intervention could be an alternative treatment modality even without performing preprocedural angiography.
Compound 529904: 1-(Propyldisulfanyl)prop-1-ene

Chemical compound data from PubChem database. IUPAC Name: 1-(prop-1-enyldisulfanyl)propane. Molecular Formula: C6H12S2. Molecular Weight: 148.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526967: Methyl 2-(3-nitrophenyl)acetate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(3-nitrophenyl)acetate. Molecular Formula: C9H9NO4. Molecular Weight: 195.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Pulmonary toxicity and gene expression changes in response to whole-body inhalation exposure to multi-walled carbon nanotubes in rats-Dataset

Nanomaterials represent a new class of materials with numerous industrial applications. Considering the projected increase in the production and use of nanomaterials, a corresponding increase in occupational exposure to nanomaterials and their resulting adverse health effects may be anticipated among workers. There is substantial evidence in the literature, based on cell culture and animal studies, supporting the potential toxicity and detrimental health effects associated with exposure to nanomaterials. Intervention and/or prevention of adverse health effects associated with occupational exposure to toxic nanomaterials is a concern for health providers and regulatory and non-regulatory government agencies as the use of nanomaterials expand. A key element in the intervention and/or prevention of the adverse health effects associated with occupational exposure to toxic nanomaterials is a clear understanding of the molecular mechanisms underlying the pulmonary toxicity induced by nanomaterials.

Due to its physicochemical and mechanical properties, multi-walled carbon nanotubes (MWCNT) have found many industrial applications. There is potential for human exposure to MWCNT or products that contain MWCNT both during the production and use of the materials that contain MWCNT. The objectives of the current study were to investigate MWCNT-induced lung toxicity and the molecular mechanisms underlying that toxicity. A rat inhalation exposure model was employed to determine the lung toxicity induced by MWCNT. Global gene expression profiles in the lung and blood were conducted to determine the molecular mechanisms underlying MWCNT-induced lung toxicity.
FY 2005 Children's Bureau Competitive Cooperative Agreements and Discretionary Grant Awards

This document provides a list of Children's Bureau discretionary grants and cooperative agreements awarded in fiscal year 2005:

Developing Adoption Services and Supports for Youth Who Wish to Retain Contact with Family Members in Order to Improve Permanency Outcomes (CFDA # 93.652)
up to $300,000 per year for 5 years

National Quality Improvement Center on the Privatization of Child Welfare Services (CFDA # 93.670)
up to $900,000 per year for 5 years

National Data Archive on Child Abuse and Neglect (CFDA # 93.670)
up to $600,000 per year for 5 years

Ithaca, NY

Consortium for Longitudinal Studies of Child Abuse and Neglect (LONGSCAN) (CFDA #93.670)
up to $250,000 per year for 5 years

Seattle, WA

Chapel Hill, NC ($500,000 per year for Coordinating Center)

Chapel Hill, NC

Chicago, IL

San Diego, CA

Baltimore, MD

up to $475,000 per year for 4 years

Santa Cruz, CA

Philadelphia, PA

West Covina, CA

Grand Rapids, MI

Knoxville, TN

Baltimore, MD

Providence, RI

Demonstration Projects That Improve Child Well-Being by Fostering Healthy Marriages Within Underserved Communities (CFDA # 93.670)
up to $150,000 per year for 4 years

Washington, DC

Bayfield, WI

Long Island City, NY

Charleston, SC

Starkville, MS

Sewickly, PA

Rockford, IL

Oakland, CA

Trenton, NJ

Grants to Tribes, Tribal Organizations, and Migrant Programs for Community-Based Child Abuse Prevention Programs (CFDA #93.590)
up to $142,000 per year for 3 years

Toppenish, WA

Anza, CA

Neshoba, MS

Model Development or Replication to Implement the CAPTA Requirement to Identify and Serve Substance Exposed Newborns (CFDA # 93.551)
up to $250,000 per year for 5 years

Denver, CO

Eugene, OR

Toledo, OH

Boston, MA

Training of Child Welfare Agency Supervisors in the Effective Delivery and Management of Federal Independent Living Service for Youth in Foster Care (CFDA #93.556)
up to $250,000 per year for 3 years

San Francisco, CA

Boston, MA

New York City, NY

Louisville, KY

Houston, TX

Iowa City, IA

Metadata-only record linking to the original dataset. Open original dataset below.
Drug Abuse Warning Network (DAWN): Findings From Drug-Related Emergency Department Visits, 2021

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related ED visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.Clickhereto view the 2021 final report.
Compound 528198: Benzoic acid, 2,3-dihydroxy, methyl ester, DTBS

Chemical compound data from PubChem database. IUPAC Name: methyl 2,2-ditert-butyl-1,3,2-benzodioxasilole-4-carboxylate. Molecular Formula: C16H24O4Si. Molecular Weight: 308.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528963: Phenol, 4-(1-ethylbutyl)-2-nitro

Chemical compound data from PubChem database. IUPAC Name: 4-hexan-3-yl-2-nitrophenol. Molecular Formula: C12H17NO3. Molecular Weight: 223.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Achieving sustainable quality in maternity services – using audit of incontinence and dyspareunia to identify shortfalls in meeting standards

Background
          Some complications of childbirth (for example, faecal incontinence) are a source of social embarrassment for women, and are often under reported. Therefore, it was felt important to determine levels of complications (against established standards) and to consider obstetric measures aimed at reducing them.
        
        
          Methods
          Clinical information was collected on 1036 primiparous women delivering at North and South Staffordshire Acute and Community Trusts over a 5-month period in 1997. A questionnaire was sent to 970 women which included self-assessment of levels of incontinence and dyspareunia prior to pregnancy, at 6 weeks post delivery and 9 to 14 months post delivery.
        
        
          Results
          The response rate was 48%(470/970). Relatively high levels of obstetric interventions were found. In addition, the rates of instrumental deliveries differed between the two hospitals. The highest rates of postnatal symptoms had occurred at 6 weeks, but for many women problems were still present at the time of the survey. At 9–14 months high rates of dyspareunia (29%(102/347)) and urinary incontinence (35%(133/382)) were reported. Seventeen women (4%) complained of faecal incontinence at this time. Similar rates of urinary incontinence and dyspareunia were seen regardless of mode of delivery.
        
        
          Conclusion
          Further work should be undertaken to reduce the obstetric interventions, especially instrumental deliveries. Improvements in a number of areas of care should be undertaken, including improved patient information, improved professional communication and improved professional recognition and management of third degree tears. It is likely that these measures would lead to a reduction in incontinence and dyspareunia after childbirth.
Compound 529364: Ile isoBOC TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 3-methyl-2-(2-methylpropoxycarbonylamino)pentanoate. Molecular Formula: C17H35NO4Si. Molecular Weight: 345.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528420: Dihydrochalcone, 2',4',6'-trihydroxy, tris-TMS

Chemical compound data from PubChem database. IUPAC Name: 1-phenyl-3-[2,4,6-tris(trimethylsilyloxy)phenyl]propan-1-one. Molecular Formula: C24H38O4Si3. Molecular Weight: 474.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Sample Size and Population Estimates Tables (Standard Errors and P Values) - 8.1 to 8.13

These detailed tables show standard errors for sample sizes and population estimates from the 2012 National Survey on Drug Use and Health (NSDUH). Standard errors for samples sizes and population estimates are provided by age group, gender, race/ethnicity, education level, employment status, geographic area, pregnancy status, college enrollment status, and probation/parole status.
Quarterly Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information

The Quarterly Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information files contain formulary, pharmacy network, and pricing data for Medicare Prescription Drug Plans and Medicare Advantage (MA) Prescription Drug Plans (with the exception of employer and Program of All-Inclusive Care for the Elderly plans).

 

These non-identifiable files are available on a quarterly basis and are comprised of the following tables:


	Plan Information - Information such as plan name, contract ID, plan ID, service area, and plan type.
	Geographic Locator - MA and Prescription Drug Plans region codes and county codes.
	Basic Drugs Formulary - Formulary details for each plan including National Drug Codes (NDCs), cost share tier level, and indicators for step therapy, quantity limits, prior authorization, and a newly added Selected Drug flag.
	Excluded Drugs Formulary - Enhanced alternative plans may elect to provide a supplemental benefit and cover excluded drugs. File includes formulary details for excluded drugs that are covered by the plan (for enhanced alternative plans only).
	Beneficiary Cost - Plan level cost sharing details for preferred, non-preferred, and mail order network pharmacies.
	Pharmacy Network - National Provider Identifier (NPI) numbers for each network pharmacy including preferred, retail, and mail order indicators, and brand, generic, and selected drug dispensing fees for 30/60/90 days supply, respectively.
	Pricing - Plan level average monthly costs for formulary Part D drugs (note: this table is only available in the quarterly files).
	Indication Based Coverage Formulary File - Includes drugs covered based on FDA-approved indication for each plan.
	Insulin Beneficiary Cost File - Plan level copay and coinsurance amounts for insulin at preferred, non-preferred and mail order network pharmacies.


 

These are large files and can take time to download. 

 

Please read the “Agreement for Use” in the Resources section below. This document contains important information regarding timeframes for obtaining data as well as data accuracy and integrity.

 

The Monthly Prescription Drug Plan Formulary and Pharmacy Network Information is also available to access for the monthly level information.

 

Please note:  The Part D benefit year information for plans become available in October of the year prior. For example, year 2025 data is available in the fourth quarter file of 2024. Year 2025 data continues to be available in the Q1-Q3 2025 files, then in the fourth quarter of 2025 year 2026 data becomes available. 

Estimated release dates for upcoming 2026 quarterly data (files reflect data for the quarter that ended the month before the file was released):


	7/29/26


Files older than contract year 2019 can be purchased.
Compound 527334: 2-(2,4-Dimethylphenyl)adamantane

Chemical compound data from PubChem database. IUPAC Name: 2-(2,4-dimethylphenyl)adamantane. Molecular Formula: C18H24. Molecular Weight: 240.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529286: 3-Heptyne, 2,2,6-trimethyl

Chemical compound data from PubChem database. IUPAC Name: 2,2,6-trimethylhept-3-yne. Molecular Formula: C10H18. Molecular Weight: 138.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Initial injury-related visits to hospital emergency departments, by sex, age, and intent and mechanism of injury: United States

<strong>On December 20 2021, all estimates and standard errors for 2017–2018 were revised in this table to correct programming errors.</strong>

Data on initial injury-related visits to hospital emergency departments, by sex, age, and intent and mechanism of injury. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. Due to a change in national medical data coding standards in 2015, from the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) to the ICD-10-CM, the definition for injuries and injury subcategories changed for the 2017 reporting period and beyond. Results from 2017 and subsequent years should not be compared with previous reporting periods. Any observed changes in trends across this transition period should not be considered. Data for 2016 are not included. Additional information regarding injury definitions and categorization of injuries by mechanism and intent of injury is available at: https://www.cdc.gov/nchs/injury/injury_tools.htm. Note that the data file available here has more recent years of data than what is shown in the PDF or Excel version.

SOURCE: NCHS, National Hospital Ambulatory Medical Care Survey. For more information on the National Hospital Ambulatory Medical Care Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus17_appendix.pdf.
Compound 528666: Penicillamine, mono-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-amino-3-methyl-3-sulfanylbutanoate. Molecular Formula: C8H19NO2SSi. Molecular Weight: 221.39. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
PII - Training and Technical Assistance Project (PII-TTAP)

The PII-TTAP team provides training and technical assistance to support the PII grantees in better meeting the needs of children and families by developing/adapting, implementing, and scaling up interventions in child welfare. PII-TTAP accomplishes this by providing innovative yet practical training and technical assistance; building capacity for implementation within PII grantee organizations through knowledge dissemination; developing tools for effective application and transfer of implementation best practices; and actively coordinating and collaborating in implementation and evaluation activities.

Learn more about PII-TTAP.

Materials

Metadata-only record linking to the original dataset. Open original dataset below.